Clinical Trials
5 trialsNCT06312176 2026-05-22
MK-2870-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06966700 2026-05-22
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04895358 2026-03-11
KEYNOTE-B49
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT02555657 2021-12-10
KEYNOTE-119
Merck Sharp & Dohme LLC
Phase 3 Completed